Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients
Imterat M, Harter P, Rhiem K, Heitz F, Schneider S, Concin N, Moubarak M, Welz J, Vrentas V, Traut A, Hahnen E, et al. (2023)
Cancers 15(9): 2534.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
cancers-15-02534-v2.pdf
632.55 KB
Autor*in
Imterat, Majdi;
Harter, Philipp;
Rhiem, Kerstin;
Heitz, Florian;
Schneider, Stephanie;
Concin, Nicole;
Moubarak, Malak;
Welz, Julia;
Vrentas, Vasileios;
Traut, Alexander;
Hahnen, Eric;
Schmutzler, Rita
Alle
Alle
Einrichtung
Abstract / Bemerkung
Data on deleterious variants in genes other than BRCA1/2 remain limited. A retrospective cohort study was performed, including primary OC cases with TruRisk germline gene panel testing between 2011 and 2020. Patients with testing after relapse were excluded. The cohort was divided into three groups: (A) no mutations, (B) deleterious BRCA1/2 mutations, and (C) deleterious mutations in other genes. A total of 702 patients met the inclusion criteria. Of these 17.4% (n = 122) showed BRCA1/2 mutations and a further 6.0% (n = 42) in other genes. Three-year overall survival (OS) of the entire cohort was significantly longer in patients with germline mutations (85%/82.8% for cohort B/C vs. 70.2% for cohort A, p < 0.001) and 3-year progression-free survival (PFS) only for cohort B (58.1% vs. 36.9%/41.6% in cohort A/C, p = 0.002). In multivariate analysis for the subgroup of advanced-stages of high-grade serous OC, both cohorts B/C were found to be independent factors for significantly better outcome, cohort C for OS (HR 0.46; 95% CI 0.25-0.84), and cohort B for both OS and PFS (HR 0.40; 95% CI 0.27-0.61 and HR 0.49; 95% CI 0.37-0.66, respectively). Germline mutations were detected in a quarter of OC patients, and a quarter of those in genes other than BRCA1/2. Germline mutations demonstrate in our cohort a prognostic factor and predict better prognosis for OC patients.
Stichworte
BRCA1/2;
RAD51C/D;
BRIP1;
PALB2;
ovarian cancer;
survival
Erscheinungsjahr
2023
Zeitschriftentitel
Cancers
Band
15
Ausgabe
9
Art.-Nr.
2534
Urheberrecht / Lizenzen
eISSN
2072-6694
Page URI
https://pub.uni-bielefeld.de/record/2979534
Zitieren
Imterat M, Harter P, Rhiem K, et al. Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients. Cancers. 2023;15(9): 2534.
Imterat, M., Harter, P., Rhiem, K., Heitz, F., Schneider, S., Concin, N., Moubarak, M., et al. (2023). Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients. Cancers, 15(9), 2534. https://doi.org/10.3390/cancers15092534
Imterat, Majdi, Harter, Philipp, Rhiem, Kerstin, Heitz, Florian, Schneider, Stephanie, Concin, Nicole, Moubarak, Malak, et al. 2023. “Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients”. Cancers 15 (9): 2534.
Imterat, M., Harter, P., Rhiem, K., Heitz, F., Schneider, S., Concin, N., Moubarak, M., Welz, J., Vrentas, V., Traut, A., et al. (2023). Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients. Cancers 15:2534.
Imterat, M., et al., 2023. Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients. Cancers, 15(9): 2534.
M. Imterat, et al., “Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients”, Cancers, vol. 15, 2023, : 2534.
Imterat, M., Harter, P., Rhiem, K., Heitz, F., Schneider, S., Concin, N., Moubarak, M., Welz, J., Vrentas, V., Traut, A., Hahnen, E., Schmutzler, R., du Bois, A., Ataseven, B.: Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients. Cancers. 15, : 2534 (2023).
Imterat, Majdi, Harter, Philipp, Rhiem, Kerstin, Heitz, Florian, Schneider, Stephanie, Concin, Nicole, Moubarak, Malak, Welz, Julia, Vrentas, Vasileios, Traut, Alexander, Hahnen, Eric, Schmutzler, Rita, du Bois, Andreas, and Ataseven, Beyhan. “Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients”. Cancers 15.9 (2023): 2534.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Namensnennung 4.0 International Public License (CC-BY 4.0):
Volltext(e)
Name
cancers-15-02534-v2.pdf
632.55 KB
Access Level
Open Access
Zuletzt Hochgeladen
2024-01-23T13:49:55Z
MD5 Prüfsumme
d7a0532e956071ce945593446f570989
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Quellen
PMID: 37174000
PubMed | Europe PMC
Suchen in